We are proud to share that Calculus portfolio companies Oxford BioTherapeutics and C4X have been recognised in the 2026 edition of The Sunday Times 100 Tech, ranking Britain’s fastest-growing private technology companies.
For Oxford BioTherapeutics this milestone reflects the success of their OGAP®-Verify discovery platform and the dedication of their exceptional team.
The ranking also recognises C4X’s impressive track record in successful partnerships for small molecule drug discovery programs in immuno-inflammation.
About Calculus Capital
Calculus pioneered tax-efficient investing through the launch of the UK’s first approved EIS in 1999. It has subsequently launched a VCT and a Knowledge Intensive EIS Fund. Calculus gives investors access to a portfolio of high-growth, UK-based private companies across the fastest growing sectors in the UK – Technology, Healthcare and Entertainment. Over the past 25 years, Calculus has built a strong reputation of delivering profitable portfolio company exits. www.calculuscapital.com